-
Mashup Score: 0Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients - 1 year(s) ago
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Northwestern Medicine Launches a Hispanic Program for Patients With Lung and Thoracic Diseases - 1 year(s) ago
The Northwestern Medicine Canning Thoracic Institute Hispanic Program was recently launched to offer personalized care for lung and thoracic patients in their native language, making life-saving care more accessible for the Hispanic community and people who prefer to speak Spanish by removing cultural and linguistic barriers.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Northwestern Medicine Launches a Hispanic Program for Patients With Lung and Thoracic Diseases @NM_Lung #lcsm https://t.co/UOwPsIm8XD
-
-
Mashup Score: 0
Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Martin Cannon, PhD, of @uamscancer, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type. #oncology https://t.co/ab14NO7nUk
-
-
Mashup Score: 1Radical Cystectomy or Bladder Preservation: Understanding Optimal Therapy for Locally Advanced Bladder Cancer - 1 year(s) ago
Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who may not benefit from standard approaches.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Radical Cystectomy or Bladder Preservation: Understanding Optimal Therapy for Locally Advanced Bladder Cancer @ndesai2005 @utswcancer #blcsm https://t.co/6SEqQiqsMY
-
-
Mashup Score: 0Fox Chase Researcher Receives Grant for Study of RNA, Telomerase and Implications for Disease - 1 year(s) ago
A Fox Chase Cancer Center researcher has been awarded a $2.5 million grant from the National Institute of General Medical Sciences to investigate RNA structure and stability, work that has implications for cancer, Alzheimer’s, and other degenerative diseases and continues the Fox Chase legacy of basic research.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Fox Chase Researcher Receives Grant for Study of RNA, Telomerase and Implications for Disease @FoxChaseCancer #oncology #medtwitter https://t.co/UBMXB72va4
-
-
Mashup Score: 1Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer - 1 year(s) ago
The novel HER2-targeted bispecific antibody zanidatamab in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in patients with advanced HER2-positive breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer @ASCO #ASCOBT23 #bcsm https://t.co/uLENXUrR15
-
-
Mashup Score: 0Bredel Findings Address Understanding of Diffuse Gliomas - 1 year(s) ago
A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Bredel Findings Address Understanding of Diffuse Gliomas @UABHeersink, @ONealCancerUAB #btsm https://t.co/copho3N8Um
-
-
Mashup Score: 0Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma - 1 year(s) ago
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma. @EHA_Hematology #EHA2023 #mmsm https://t.co/WCLW6UnDgC
-
-
Mashup Score: 1Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond - 1 year(s) ago
Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Positive early results from a phase 1 study of the EGFR x HER3 ADC BL-B01D1 reflect the agent’s potential to expand options in later lines for certain patient subgroups in lung cancer. @MSKCancerCenter @ASCO #ASCO23 #lcsm https://t.co/c0uhwjbxdK https://t.co/wy3j19aq0D
-
-
Mashup Score: 0LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC - 1 year(s) ago
David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment for patients with RCC and shared details from the LITESPARK-024 trial. @harvardmed @kidneycan #KCRS23 #kcsm https://t.co/FmTI2M9P3v
-
Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients @danafarber #mmsm https://t.co/QQtGWCI2Cn